- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | - / - |
| Spread | - |
| Schluss Vortag | 0,000001 $ |
| Gehandelte Stücke | 351.004 |
| Tagesvolumen Vortag | - |
| Tagestief 0,000001 $ Tageshoch 0,000001 $ | |
| 52W-Tief 0,000001 $ 52W-Hoch 0,000024 $ | |
| Jahrestief 0,000001 $ Jahreshoch 0,000001 $ | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Nasdaq OTC Other | 0,000001 $ | 0 % | 0,000001 $ | 20.02.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 20.02.26 | 0,000001 | 0 |
| 25.09.25 | 0,000024 | 0 |
| 09.04.25 | 0,000001 | 0 |
| 07.03.25 | 0,000001 | 1 |
| 13.11.24 | 0,000001 | 0 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | - | - |
| 1 Monat | 0,000024 $ | -95,83% |
| 6 Monate | 0,000001 $ | 0,00% |
| 1 Jahr | 0,000001 $ | 0,00% |
| 5 Jahre | 0,001 $ | -99,90% |
| Aktientyp | Stammaktie |
Viropro, Inc. Signs a Binding Letter of Agreement For a Multi-Million Development Contract With NASDAQ-Listed Spectrum Pharmaceuticals, Inc. Irvine, CA & Montreal, Canada, Wednesday, January 5, 2011 – Viropro is pleased to announce it has signed a binding Letter of Agreement (“LOA”) with Spectrum Pharmaceuticals, Inc. of Irvine, CA, for the development and clinical production of a biosimilar version of Rituximab, a monoclonal antibody currently used in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. As part of this LOA, Spectrum will also license the rights to certain technology that will be used in the development of the Rituximab biosimilar. The LOA calls for payments of milestones over an expected 36 months time span. The LOA also calls for the payment of royalties from ensuing sales.
von Reuters:
Spectrum Pharmaceuticals, Inc. To Develop Biosimilar Rituximab; Signs A Binding Letter Of Agreement With Viropro, Inc. Wednesday, 5 Jan 2011 07:00am EST Spectrum Pharmaceuticals, Inc. announced that it has signed a letter of agreement with Viropro, Inc., for the development of a biosimilar version of the monoclonal antibody drug rituximab (marketed by Genentech/Roche).
der markt für diese biosimilars ist riesig...selbst wenn viropro nur
einen teil des kuchens bekommt wäre hierfür eine völlige neubewertung der company notwendig!
